J Control Release
January 2003
A general drug delivery approach for increasing oral bioavailability of purine and pyrimidine analogues such as acyclovir may be to link these compounds reversibly to stabilized dipeptide pro-moieties with affinity for the human intestinal di/tri-peptide transporter, hPepT1. In the present study, novel L-Glu-Sar and D-Glu-Ala ester prodrugs of acyclovir and 1-(2-hydroxyethyl)-linked thymine were synthesized and their affinities for hPepT1 in Caco-2 cells were determined. Furthermore, the degradation of the prodrugs was investigated in various aqueous and biological media and compared to the corresponding hydrolysis of the prodrug valaciclovir.
View Article and Find Full Text PDFL-Valacyclovir, a prodrug of acyclovir, is a substrate for the peptide transporter (PepT1) in the intestinal mucosa, which accounts for its higher than expected oral bioavailability. The substrate activity of L-valacyclovir for PepT1 is surprising, particularly when one considers that the molecule has the structural features of a nucleoside rather than a peptide. In an attempt to better understand the structure-transport relationships (STR) for the interactions of L-valacyclovir with PepT1, analogs of this molecule with structural changes in the guanine moiety were synthesized and their substrate activity for PepT1 in Caco-2 cell monolayers was determined.
View Article and Find Full Text PDFA new limonoid was isolated from the bark of Khaya senegalensis and identified as 2,6-dihydroxyfissinolide. The assignments of some signals in the (13)C NMR spectrum of fissinolide have been reversed and the signals of the (1)H NMR spectrum of methyl 3beta-acetoxy-6-hydroxy-1-oxomeliac-14-enoate have been assigned. The limonoids only showed moderate antiprotozoal activities.
View Article and Find Full Text PDF